Published : Oct-2020
No. of Pages : 58
1.1 List of Tables
1.2 List of Figures
2 Ulcerative Colitis: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of UC
3.4.4 Forecast Assumptions and Methods: Total and Diagnosed Prevalent Cases of UC
3.4.5 Germany
3.4.6 Italy
3.4.7 Spain
3.4.8 UK
3.4.9 Japan
3.4.10 Canada
3.4.11 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of UC by severity
3.4.12 8MM
3.4.13 Forecast Assumptions and Methods: Post-operative UC Cases
3.5 Epidemiological Forecast for UC (2019-2029)
3.5.1 Diagnosed Incident Cases of UC
3.5.2 Age-Specific Diagnosed Incident Cases of UC
3.5.3 Sex-Specific Diagnosed Incident Cases of UC
3.5.4 Diagnosed Prevalent Cases of UC
3.5.5 Age-Specific Diagnosed Prevalent Cases of UC
3.5.6 Sex-Specific Diagnosed Prevalent Cases of UC
3.5.7 Diagnosed Prevalent Cases of UC by Severity for Ages <18 Years
3.5.8 Diagnosed Prevalent Cases of UC by Severity for Ages ?18 Years
3.5.9 Post-Operative UC Cases Among Diagnosed Prevalent Cases of UC
3.5.10 Total Prevalent Cases of UC
3.5.11 Age-Specific Total Prevalent Cases of UC
3.5.12 Sex-Specific Total Prevalent Cases of UC
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Coronavirus Disease 2019 Impact
3.6.3 Limitations of the Analysis
3.6.4 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 Primary Research - Prescriber Survey
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About GlobalData
4.5 Contact Us
4.6 Disclaimer
List of Tables
Table 1: Summary of Newly Added Data Types
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for UC and IBD
Table 4: High-Prescribing Physicians (non-KOLs) Surveyed for Severity of UC for ages ?18 years, by Country
List of Figures
Figure 1: 8MM, Diagnosed IncidentCases of UC, Both Sexes, N, All Ages ,2019 and 2029
Figure 2: 8MM, Diagnosed Prevalent Cases of UC, Both Sexes, N, All Ages ,2019 and 2029
Figure 3: 8MM, Total Prevalent Cases of UC, Both Sexes, N, All Ages,2019 and 2029
Figure 4: 8MM, Diagnosed Incidence of UC, Men and Women, Cases per 100,000 Population, All Ages, 2019
Figure 5: 8MM, Diagnosed Prevalence of UC, Men and Women, %, All Ages, 2019
Figure 6: 8MM, Total Prevalence of UC, Men and Women, %, All Ages, 2019
Figure 7: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of UC
Figure 8: 8MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of UC
Figure 9: 8MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of UC
Figure 10: 8MM, Sources Used to Forecast the Post-Operative UC Cases among Diagnosed Prevalent Cases of UC
Figure 11: 8MM, Sources Used to Forecast the Severity of Diagnosed Prevalent Cases of UC for Ages <18 years
Figure 12: 8MM, Diagnosed Incident Cases of UC, N, Both Sexes, All Ages, 2019
Figure 13: 8MM, Diagnosed Incident Cases of UC by Age, N, Both Sexes, 2019
Figure 14: 8MM, Diagnosed Incident Cases of UC by Sex, N, All Ages, 2019
Figure 15: 8MM, Diagnosed Prevalent Cases of UC, N, Both Sexes, All Ages, 2019
Figure 16: 8MM, Diagnosed Prevalent Cases of UC by Age, N, Both Sexes, 2019
Figure 17: 8MM, Diagnosed Prevalent Cases of UC by Sex, N, All Ages, 2019
Figure 18: 8MM, Diagnosed Prevalent Cases of UC by Severity, N, Ages <18 years, 2019
Figure 19: 8MM, Diagnosed Prevalent Cases of UC by Severity, N, Ages ?18 Years, 2019
Figure 20: 8MM, Post-Operative UC Cases Among Diagnosed Prevalent Cases of UC, 2019
Figure 21: 8MM, Total Prevalent Cases of UC, N, Both Sexes, All Ages, 2019
Figure22: 8MM, Total Prevalent Cases of UC by Age, N, Both Sexes, 2019
Figure 23: 8MM, Total Prevalent Cases of UC by Sex, N, All Ages, 2019
